Home › NDC Lookup › RxCUI directory › RxCUI 2472321

Vibegron 75 MG Oral Tablet [Gemtesa] — RxCUI 2472321

RxNorm drug concept · Semantic branded drug
RxCUI 2472321 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2472321
Official nameVibegron 75 MG Oral Tablet [Gemtesa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asGemtesa 75 MG Oral Tablet; GEMTESA 75 MG Once-Daily Oral Tablet
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)84,266 prescriptions · 48 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Vibegron: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats overactive bladder in adults. That means sudden urges to urinate, urge leakage and going often. Gemtesa is also used for these symptoms in men who take medicine for BPH.
  • Take one tablet by mouth once a day, with or without food. Swallow it whole with a glass of water. If swallowing is hard, adults can crush it into a tablespoon of applesauce and ta...
  • The most common ones are headache, urinary tract infection, cold-like symptoms such as a stuffy nose or sore throat, diarrhea and nausea. Most are not serious, but tell us if they...
  • Get emergency help right away if your face, lips, tongue or throat swells. That is angioedema and can be life-threatening. Also call your doctor if you have trouble passing urine o...
📖 Read our full Vibegron guide →

🕸️ Concept Web — How Vibegron 75 MG Oral Tablet [Gemtesa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Vibegron 75 MG Oral Tablet [Gemtesa] RxCUI 2472321

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Vibegron 2472254
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gemtesa 2472316
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Vibegron Oral Tablet 2472314
    • Vibegron Oral Product 2472312
    • Vibegron Pill 2472313
    • Vibegron Oral Tablet [Gemtesa] 2472318
    • Gemtesa Oral Product 2472319
    • Gemtesa Pill 2472320
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Vibegron 75 MG Oral Tablet SCD · 2472315
  • Vibegron 75 MG SCDC · 2472311
  • Vibegron Oral Tablet SCDF · 2472314
  • Vibegron Oral Product SCDG · 2472312
  • Vibegron Pill SCDG · 2472313

Brand-Name Concepts

  • Vibegron 75 MG [Gemtesa] SBDC · 2472317
  • Vibegron Oral Tablet [Gemtesa] SBDF · 2472318
  • Gemtesa Oral Product SBDG · 2472319
  • Gemtesa Pill SBDG · 2472320
  • Gemtesa BN · 2472316

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 2472321 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73336-0075-07 1 BOTTLE in 1 CARTON (73336-075-07) / 7 TABLET, FILM COATED... GEMTESA Sumitomo Pharma America, Inc. 2020-12-29
73336-0075-30 30 TABLET, FILM COATED in 1 BOTTLE (73336-075-30) GEMTESA Sumitomo Pharma America, Inc. 2020-12-29
73336-0075-90 90 TABLET, FILM COATED in 1 BOTTLE (73336-075-90) GEMTESA Sumitomo Pharma America, Inc. 2020-12-29
Observed labelers: Sumitomo Pharma America, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$16.4635
Range $16.4635–$16.4635 · middle 50% $16.4635–$16.4635 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.